AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Novel Antibody for Inhibiting Nodal-Dependent Activity

Technology Benefits
High affinity to NodalHighly selectiveEasy to scale production
Detailed Technology Description
Novel monoclonal antibody that inhibits the binding of Nodal to the Activin receptor complex #therapeutics #antibody #biomedical #researchtool
*Abstract

Northwestern researchers, together with Italian collaborators, have characterized a monoclonal antibody that inhibits the activity of Nodal, a growth factor driving abnormal growth in a variety of cancers. In normal development, Nodal is important in maintaining stem cell pluripotency, and subsequently disappears in most normal adult tissues. The inventors discovered, however, that Nodal is reactivated in aggressive tumor cells and is also associated with invasive disease states across many cancer types. Currently, existing technologies for inhibiting Nodal signaling are based on suppressing Nodal expression using antisense technology or commercial polyclonal antibodies, and there is no available Nodal-based ELISA. The novel monoclonal antibody described here is highly selective and possesses a high affinity to Nodal, and can be used effectively as a capture antibody in a sandwich-based ELISA. In addition, because it is easy to scale the production of this antibody, it is an ideal candidate for pharmaceutical development. 

*Inventors
Mary Hendrix*Elisabeth Seftor Richard SeftorMenotti Ruvo AnnaMaria SandomenicoAntonio LeonardiLuca SanguignoLuigi StrizziZhila Khalkhali-Ellis
*Publications
Topczewska JM, Postovit L-M, Margaryan NV, Sam A, Hess AR, Wheaton WW, Nickoloff BJ, Topczewski J and Hendrix MJC (2006). Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nature Medicine, 12, 925-932. Lawrence MG, Margaryan NV, Loessner D, Collins A, Kerr KM, Turner M, Seftor EA, Stephens CR, Lai J, APC BioResource, Postovit L-M, Clements JA, Hendrix MJC (2011). Reactivation of Embryonic Nodal Signaling is Associated with Tumor Progression and Promotes the Growth of Prostate Cancer Cells. Prostate, 71(11).
Country/Region
USA

For more information, please click Here
Mobile Device